Robert Schmid

Acino International AG develops and manufactures pharmaceuticals in novel drug delivery form. The firm provides drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. It offers abelcet, bactiflox, clopacin, dolonica, hydronica, neurorubine, olfen and spasfon. The company was founded in 1836 and is headquartered in Zurich, Switzerland.

Acino AG engages in the development and manufacture of pharmaceutical products. It also offers services such as registration, procurement, contract manufacturing, packaging, and logistics. Its products include solid oral dosage forms, patches, as well as biodegradable and subcutaneous implants. The company was founded by Wilfried Fischer in 1997 and is headquartered in Miesbach, Germany.